Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ABVC
Upturn stock ratingUpturn stock rating

ABVC Biopharma Inc (ABVC)

Upturn stock ratingUpturn stock rating
$4.68
Last Close (24-hour delay)
Profit since last BUY559.15%
upturn advisory
Strong Buy
BUY since 93 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/09/2025: ABVC (3-star) is a STRONG-BUY. BUY since 93 days. Profits (559.15%). Updated daily EoD!

Upturn Star Rating

rating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $2.02

1 Year Target Price $2.02

Analysts Price Target For last 52 week
$2.02 Target price
52w Low $0.4
Current$4.68
52w High $5.48

Analysis of Past Performance

Type Stock
Historic Profit 237.33%
Avg. Invested days 35
Today’s Advisory Strong Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/09/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 79.47M USD
Price to earnings Ratio -
1Y Target Price 2.02
Price to earnings Ratio -
1Y Target Price 2.02
Volume (30-day avg) 1
Beta 0.19
52 Weeks Range 0.40 - 5.48
Updated Date 07/9/2025
52 Weeks Range 0.40 - 5.48
Updated Date 07/9/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.19

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -503.56%

Management Effectiveness

Return on Assets (TTM) -10.91%
Return on Equity (TTM) -42.42%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 82445898
Price to Sales(TTM) 156.33
Enterprise Value 82445898
Price to Sales(TTM) 156.33
Enterprise Value to Revenue 162.17
Enterprise Value to EBITDA -1.9
Shares Outstanding 16981600
Shares Floating 11364913
Shares Outstanding 16981600
Shares Floating 11364913
Percent Insiders 16.47
Percent Institutions 2.28

ai summary icon Upturn AI SWOT

ABVC Biopharma Inc

stock logo

Company Overview

overview logo History and Background

ABVC Biopharma, Inc. (formerly American BriVision Corporation) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic solutions to treat unmet medical needs. Founded to develop ophthalmic products, it has broadened its focus to include oncology and other therapeutic areas.

business area logo Core Business Areas

  • Drug Development: Focused on developing and commercializing therapeutic solutions for cancer and other unmet medical needs. Lead compound is ABV-1505 for pancreatic cancer.
  • Medical Device: Develops and commercializes medical devices focused on ophthalmic treatments.

leadership logo Leadership and Structure

The leadership team consists of experienced executives in the pharmaceutical industry, including Dr. Howard Doong (CEO). The organizational structure is typical of a small-cap biopharmaceutical company.

Top Products and Market Share

overview logo Key Offerings

  • ABV-1505: ABV-1505 is a novel drug candidate in clinical development for the treatment of pancreatic cancer. Market share is currently 0% but aims to compete in the pancreatic cancer treatment market. Competitors include Eli Lilly, Roche, and Bristol Myers Squibb, which have approved pancreatic cancer treatments.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition. It is heavily regulated by agencies like the FDA.

Positioning

ABVC Biopharma is a small-cap company attempting to develop novel therapies in competitive markets. Its competitive advantage lies in its unique drug candidates and partnerships.

Total Addressable Market (TAM)

The global oncology market is expected to reach hundreds of billions of dollars. ABVC Biopharma aims to capture a portion of this market with its cancer therapies. Exact TAM for ABV-1505 is dependent on successful clinical trials and FDA approval.

Upturn SWOT Analysis

Strengths

  • Novel drug candidates
  • Experienced management team
  • Strategic partnerships

Weaknesses

  • Limited financial resources
  • Dependence on clinical trial outcomes
  • Small-cap size

Opportunities

  • Successful clinical trial results
  • FDA approval of drug candidates
  • Potential for acquisitions or partnerships

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from larger pharmaceutical companies

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • RHHBY
  • BMY

Competitive Landscape

ABVC Biopharma faces significant competition from larger pharmaceutical companies with greater resources and established market presence. Its success hinges on differentiating its drug candidates and securing partnerships.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is limited due to the company's development stage. Potential for growth depends on future FDA approvals.

Future Projections: Future growth projections depend on successful clinical trials and FDA approval of ABV-1505 and other drug candidates. Analyst estimates vary widely.

Recent Initiatives: Recent initiatives include progressing ABV-1505 through clinical trials and seeking partnerships for commercialization.

Summary

ABVC Biopharma is a high-risk, high-reward biopharmaceutical company in the clinical stage, meaning it currently lacks a strong market position. Its primary asset, ABV-1505, offers hope for capturing market share contingent upon clinical trial success and regulatory approval. The company's financial health relies heavily on fundraising and strategic partnerships. Investors should carefully monitor clinical trial outcomes and regulatory developments.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Market research reports
  • Analyst reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Data may be outdated and subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About ABVC Biopharma Inc

Exchange NASDAQ
Headquaters Fremont, CA, United States
IPO Launch date 2017-10-11
CEO & Interim CFO Dr. Uttam Yashwant Patil Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 16
Full time employees 16

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is headquartered in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.